The REPREVIO trial found that vedolizumab treatment within 4 weeks of ileocolonic resection was more effective than placebo in preventing postoperative endoscopic recurrence of Crohn’s disease in patients with risk factors for recurrence. The study evaluated the efficacy and safety of vedolizumab in this patient population, with vedolizumab resulting in a lower modified Rutgeerts score at 26 weeks compared to placebo. The vedolizumab group also had a lower incidence of severe endoscopic and histologic recurrence. The study suggests that vedolizumab could be a prophylactic treatment for individuals at risk for recurrence of Crohn’s disease following surgery.
Source link
Vedolizumab Reduces Postoperative Crohn’s Disease Recurrence
